Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
jnce · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Jounce Therapeutics, Inc. (JNCE) measures how much investors pay for each dollar of the company's trailing earnings. JNCE's current PE ratio of N/A is calculated by dividing its stock price of $1.88 by its TTM earnings per share of -$0.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2014 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Jounce Therapeutics, Inc.You JNCE | $99M | N/A | — | -$0.99 |
 Aadi Bioscience, Inc. AADI | $95M | N/A | — | -$0.03 |
 Berkeley Lights, Inc. BLI | $87M | N/A | — | -$1.42 |
 Cyteir Therapeutics, Inc. CYT | $109M | N/A | — | -$1.25 |
 Decibel Therapeutics, Inc. DBTX | $123M | N/A | — | -$2.52 |
 HilleVax, Inc. HLVX | $105M | N/A | — | -$3.00 |
 Insight Molecular Diagnostics Inc. IMDX | $154M | N/A | — | -$1.65 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.99 | — | |
2021-12-31 FY2021 | — | $-1.82 | — | |
2020-12-31 FY2020 | — | $-1.24 | — | |
2019-12-31 FY2019 | 5.08x | $1.72 | — | |
2018-12-31 FY2018 | — | $-0.84 | — | |
2017-12-31 FY2017 | — | $-0.55 | — | |
2016-12-31 FY2016 | — | $-0.45 | — | |
2015-12-31 FY2015 | — | $-1.54 | — | |
2014-12-31 FY2014 | — | $-0.48 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Jounce Therapeutics, Inc. (JNCE) measures how much investors pay for each dollar of the company's trailing earnings. JNCE's current PE ratio of N/A is calculated by dividing its stock price of $1.88 by its TTM earnings per share of -$0.99.
Frequently asked questions
JNCE pe ratio · 6 questionsJNCE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.88 and TTM EPS of -$0.99. Data sourced from Financial Modeling Prep via JNCE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Jounce Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09